Novartis

Novartis
Fabrikstrasse 2, 4056 Basel
Novartis  
Discipline: Medicine/Pharmacology
Related:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.

#display_name

Medicine - Sep 24
Novartis announces five grant recipients of eXcellence in Ophthalmology Vision Award (XOVA) for nonprofit sustainable eye health initiatives A panel of independent ophthalmologists and optometrists selected five winners out of more than 100 entries from 34 countries -   The 2018 grants support initiatives ranging from training teachers for visio
Medicine - Sep 22

New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMD - Pre-specified analysis provides insight into ma

Medicine - Sep 21

If approved in expected timeframe, Luxturna* (voretigene neparvovec) will be first and only gene therapy available in EU to treat a rare inherited retinal disease -   Children and adults living wit

Medicine - Sep 21

Positive opinion is based on comprehensive data confirming that Sandoz biosimilar pegfilgrastim matches the reference medicine in terms of safety, efficacy and quality Sandoz seeks approval in the

Medicine - Sep 17

Alcon Experience Academy serves as umbrella for industry-leading training and educational resources for all eye care professionals New website houses a robust library of more than 500 videos, inclu

Medicine - Sep 22

Novartis to file for new Lucentis (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness In the Phase III RAINBOW study, des

Medicine - Sep 21

Children and adolescents with multiple sclerosis (MS) experience more frequent and often more severe relapses than adults with the disease, hindering their development and ability to take part in e

Medicine - Sep 17

From a sample of over 10,000 adults, 62% are worried that they may develop Alzheimer's disease and 91% believe the solution to tackling diseases lies in medical research -   79% are willing to take

Medicine - Sep 13

Treatment with Gilenya (fingolimod) substantially reduced the debilitating impact of MS, with significant decreases in key measures of disease activity vs.




website preview

Link

Medicine and Life Sciences